Congratulations to the team at AMR Hub on your official launch. SpeeDx is thrilled to work alongside you in the fight against antimicrobial resistance. On 3 August 2022, the AMR Hub...
SpeeDx have launched a new product line of research reagents to support reflex variant analysis for circulating SARS-CoV-2 variants of concern (VOC). The rapid development of PlexPrime® SARS-CoV-2 Genotyping research reagents will...
The opening of a PC2 laboratory facility at SpeeDx Sydney headquarters is an exciting milestone to celebrate. SpeeDx performs all commercial functions including research, development and manufacturing out of their...
Important clinical data published in Clinical Infectious Diseases demonstrated practical effectiveness of Resistance Guided Therapy for treating gonorrhoea. Led by Dr. Jeffrey Klausner, Professor of epidemiology and medicine at UCLA,...
Important data using ResistancePlus® MG to investigate over 1500 symptomatic vaginitis patients. Mycoplasma genitalium (Mgen) infection was more prevalent in women with bacterial vaginosis (BV) (7.0% Mgen positive) compared with...
SpeeDx is committed to continually improving and innovating diagnostics with ongoing advances spun out of our remarkable Blue Sky Research team. Our scientists are investigating an isothermal, protein-enzyme-free approach to...
Dr. Klausner, a clinical professor at UCLA, shares the details of his work with genotypic testing for ciprofloxacin susceptibility in Neisseria gonorrhoeae. The study found that routine gyrA genotyping can be...
Public Health England (PHE) is investigating two cases of extensively drug resistant (XDR) gonorrhoea recently diagnosed in the U.K. XDR gonorrhoea exhibits resistance patterns to ceftriaxone and azithromycin, the two antibiotics...
The Australian STI management guidelines have been updated and now suggest when testing for Mycoplasma genitalium that inclusion of macrolide resistance testing will guide appropriate treatment. Announced during the recent...
Mycoplasma genitalium is a little-known sexually transmitted infection affecting up to two per cent of the population. A new test developed by Australian diagnostics company SpeeDx, is helping health experts...